Equibles does not estimate personal net worth.
Get an email with a short summary when NEUROONE MEDICAL TECHNOLOGIES Corp publishes a filing, an earnings call transcript or a press release.
Get NMTC alertsDavid Rosa is recorded as CEO and Board Member at NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC). The newest filing on record that lists David Rosa as CEO and Board Member at NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) is dated March 9, 2026. Earlier roles on record: Board Member at BioRestorative Therapies, Inc. (BRTX) until July 11, 2026. BioRestorative Therapies, Inc. reported in an 8-K filed July 16, 2026 that David Rosa resigned as director, effective July 11, 2026. David Rosa has spoken on 3 earnings calls and 1 other investor event across 2 companies, most recently for Intuitive Surgical Inc on April 30, 2026. Those appearances were for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) and Intuitive Surgical Inc (ISRG). NEUROONE MEDICAL TECHNOLOGIES Corp is classified in the Medical Devices industry within the Healthcare sector. Intuitive Surgical Inc is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at NEUROONE MEDICAL TECHNOLOGIES Corp includes Dave Rosa (CEO and Board Member), Paul Buckman (Chairman), Christopher Volker (CFO and COO) and 7 others.
“On July 11, 2026, David Rosa resigned as a director of the Company and from each committee of the Board of Directors of the Company (the "Board") on which he served, including the Compensation Committee, effective immediately.”
“Before I get into my presentation, I'd like to take a moment to acknowledge the contributions of Amal Johnson to the Board of Directors and to the company. Amal joined our board in April of 2010.”
“I would like to welcome you to our first quarter fiscal 2026 financial results conference call. The company continued the positive momentum from fiscal year 2025 by making progress in a number of different areas of the business.”
“I'd like to welcome you to our fourth quarter fiscal 2025 financial results conference call. Fiscal year 2025 was the most successful year in the history of NeuroOne Medical Technologies Corporation and an inflection point for our company.”
“We made excellent progress in the third quarter of fiscal year 2025 on our financial objectives, as well as achieving successful outcomes in treating patients with our OneRF ablation system, advancing our product development programs and strengthening our management team.”
Start not stated–present
Last confirmed March 9, 2026
Start not stated–present
Last confirmed March 9, 2026
Source not stated
2021-01-01–2026-07-11
Medical Devices · Healthcare
CEO, Board Member
Medical Instruments & Supplies · Healthcare
